PriceTargets.com logo

Enveric Biosciences - ENVB Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 2,976.92%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.33 As of 12/20/2024 06:45 PM ET
▼ -0.0034 (-1.04%)

This chart shows the closing price for ENVB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Enveric Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ENVB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ENVB

Analyst Price Target is $10.00
▲ +2,976.92% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Enveric Biosciences in the last 3 months. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a 2,976.92% upside from the last price of $0.33.

This chart shows the closing price for ENVB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Enveric Biosciences. This rating has held steady since March 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/30/2024HC WainwrightReiterated RatingBuy$10.00
6/1/2022Alliance Global PartnersInitiated CoverageBuy$62.50
5/26/2022Maxim GroupLower Target$25.00
3/8/2022AegisDowngradeBuy ➝ Hold
7/8/2021AegisInitiated CoverageBuy$350.00
6/28/2021Maxim GroupInitiated CoverageBuy$300.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Enveric Biosciences logo
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Read More

Today's Range

Now: $0.33
Low: $0.31
High: $0.34

50 Day Range

MA: $0.41
Low: $0.32
High: $0.55

52 Week Range

Now: $0.33
Low: $0.30
High: $2.92

Volume

201,754 shs

Average Volume

1,665,183 shs

Market Capitalization

$3.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68

Frequently Asked Questions

What sell-side analysts currently cover shares of Enveric Biosciences?

The following Wall Street sell-side analysts have issued stock ratings on Enveric Biosciences in the last year: HC Wainwright.
View the latest analyst ratings for ENVB.

What is the current price target for Enveric Biosciences?

0 Wall Street analysts have set twelve-month price targets for Enveric Biosciences in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 2,976.9%. HC Wainwright has the highest price target set, predicting ENVB will reach $10.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $10.00 for Enveric Biosciences in the next year.
View the latest price targets for ENVB.

What is the current consensus analyst rating for Enveric Biosciences?

Enveric Biosciences currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ENVB will outperform the market and that investors should add to their positions of Enveric Biosciences.
View the latest ratings for ENVB.

What other companies compete with Enveric Biosciences?

Other companies that are similar to Enveric Biosciences include Acurx Pharmaceuticals, Cara Therapeutics, HCW Biologics, TherapeuticsMD and Marinus Pharmaceuticals. Learn More about companies similar to Enveric Biosciences.

How do I contact Enveric Biosciences' investor relations team?

Enveric Biosciences' physical mailing address is 4080 MCGINNIS FERRY ROAD SUITE 1306, ALPHARETTA GA, 30005. The company's listed phone number is (239) 302-1707 and its investor relations email address is [email protected]. The official website for Enveric Biosciences is jaypharma.co. Learn More about contacing Enveric Biosciences investor relations.